The case for & against
Bull & Bear analysis
Bearish
IM Cannabis Corp. (CSE: IMC) operates in the medical cannabis sector, focusing on the cultivation, distribution, and sale of cannabis products, primarily in Germany and Israel. A significant player in this emerging industry, IM Cannabis is poised to benefit from the recent legalization efforts in Germany, which have amplified their market opportunity. The company aims to strengthen its position amidst complex regulatory dynamics, while positioning itself strategically to exploit growth opportunities across established and new markets.
Bull says
- ↑Q4 2024 German sales surged 280% post-legalization
- ↑Q1 2025 revenue $12.5M (+4% YoY) driven by Germany
- ↑Operating expenses cut 56% YoY to $3.3M in Q1
- ↑Adjusted EBITDA positive at $0.6M vs $2.2M loss prior year
- ↑Launched 12 new strains in Germany, generating €3M sales
- ↑Strong liquidity and favorable rate sensitivity support growth
Bear says
- ↓Total liabilities rose to $41.8M, raising leverage risk
- ↓Net loss widened to $11.8M in 2024 from $10.2M in 2023
- ↓Israeli revenues fell 66%, heightening market concentration
- ↓Short interest up 39.6%, now 2.45% of the float
- ↓Accrued $0.6M for slow‐moving inventory, pressuring margins
- ↓Weak profitability metrics and negative earnings yield persist
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 06-29-2026neutral
Transcript signals
Bull points
- German government's legalization of cannabis on April 1st, alongside the anticipated reclassification by the US Drug Enforcement Administration, indicates a significant regulatory shift in the cannabis market, moving it toward mainstream acceptance.
- we have seen continuous acceleration in our sales. In April, our monthly sales were just about double the monthly average of the last six months. While it is still too early to predict how the market will continue to develop, the first month was very promising.
- by facilitating the access to medical cannabis for many new patients, the new regulations will transform the medical cannabis market in Israel.
Bear points
- Revenues for Q1 2024 were $12.1 million compared to $12.5 million in Q1 2023, a decrease of 3%. The decrease is mainly due to an exchange rate effect of about $0.2 million and decrease in average price per sale due to increased competition.
- Gross profit for Q1 2024 was $1.8 million, compared to $2.9 million in Q1 2023, a decrease of 39%. The downside is attributed mainly to the slow moving stock that was moved out at the lower prices and an exchange of differences totaling $0.4 million and $0.64 million cost of sales due to the inventory erase of the slow moving stock.
- NANA IFRS adjusted EBITDA loss in Q1 2024 was $2.1 million compared to an adjusted EBITDA loss of $1.9 million in Q1 2023 and increased losses of 10%.
Read full transcript analysis ›